Company VGI Health Technology Limited

VGI Health Technology Limited is an Australia-based biotechnology company. The Company’s MELT3 formulation of Tocotrienols (T3s) is designed to be dissolved in the mouth and then swallowed, which is used for certain non-disease and self-limiting exercise related indications, such as reduction of delayed onset muscle soreness (DOMS), improved muscle recovery after exercise and improved maintenance of muscle power. MELT3 is designed for nutraceuticals and dietary supplements. Its TransT3, a transmucosal delivery platform for T3s, is designed to enhance absorption of the T3s by facilitating sublingual and buccal (transmucosal) absorption. T3s are absorbed into the capillaries below the sublingual and buccal mucosa and then released into the blood stream. Its Tocotrienol ProDrugs (TPD) is a prodrug delivery platform for T3s designed to enhance absorption of T3s into the lymphatic system of the gut and release of T3s into the blood stream.